Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study

雷贝拉唑 医学 内科学 胃肠病学 临床终点 CYP2C19型 幽门螺杆菌 不利影响 安慰剂 随机对照试验 奥美拉唑 质子抑制剂泵 置信区间 兰索拉唑 病理 细胞色素P450 替代医学 新陈代谢
作者
Huiyun Zhu,Xue Pan,Li Zhang,Hongxin Sun,Huizhen Fan,Zhongwei Pan,Caibin Huang,Zhenwang Shi,Jin Ding,Qi Wang,Yiqi Du,Nonghua Lyu,Zhaoshen Li
出处
期刊:Chinese Medical Journal [Lippincott Williams & Wilkins]
被引量:10
标识
DOI:10.1097/cm9.0000000000002508
摘要

Abstract Background: The pharmacokinetic and clinical behaviors of many proton pump inhibitors (PPIs) in peptic ulcer treatment are altered by CYP2C19 genetic polymorphisms. This non-inferiority study evaluated the efficacy and safety of the novel PPI anaprazole compared with rabeprazole. We also explored the influence of Helicobacter pylori ( H. pylori ) infection status and CYP2C19 polymorphism on anaprazole. Methods: In this multicenter, randomized, double-blind, double-dummy, positive-drug parallel-controlled, phase III study, Chinese patients with duodenal ulcers were randomized 1:1 to receive rabeprazole 10 mg + anaprazole placebo or rabeprazole placebo + anaprazole 20 mg once daily for 4 weeks. The primary efficacy endpoint was the 4-week ulcer healing rate assessed by blinded independent review. Secondary endpoints were the proportion of patients with improved overall and individual duodenal ulcer symptoms at 4 weeks. Furthermore, exploratory subgroup analysis of the primary endpoint by H. pylori status and CYP2C19 polymorphism was conducted. Adverse events were monitored for safety. Non-inferiority analysis was conducted for the primary endpoint. Results: The study enrolled 448 patients (anaprazole, n = 225; rabeprazole, n = 223). The 4-week healing rates were 90.9% and 93.7% for anaprazole and rabeprazole, respectively (difference, −2.8% [95% confidence interval, −7.7%, 2.2%]), demonstrating non-inferiority of anaprazole to rabeprazole. Overall duodenal ulcer symptoms improved in 90.9% and 92.5% of patients, respectively. Improvement rates of individual symptoms were similar between the groups. Healing rates did not significantly differ by H. pylori status or CYP2C19 genotype for either treatment group. The incidence of treatment-emergent adverse events was similar for anaprazole (72/220, 32.7%) and rabeprazole (84/219, 38.4%). Conclusions: The efficacy of anaprazole is non-inferior to that of rabeprazole in Chinese patients with duodenal ulcers. Registration: ClinicalTrials.gov, NCT04215653.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
年轻千萍完成签到,获得积分10
1秒前
刻苦的砖头完成签到 ,获得积分10
2秒前
2秒前
哈哈完成签到,获得积分10
3秒前
wali完成签到 ,获得积分0
3秒前
free2030完成签到,获得积分10
3秒前
王梦瑶完成签到 ,获得积分10
3秒前
541完成签到 ,获得积分10
3秒前
舟舟完成签到 ,获得积分10
6秒前
陈槊诸发布了新的文献求助10
8秒前
小小完成签到 ,获得积分10
8秒前
温柔的天奇完成签到 ,获得积分10
9秒前
随风而起完成签到,获得积分10
10秒前
YHBBZ完成签到 ,获得积分10
11秒前
水牛完成签到,获得积分10
11秒前
11秒前
雪流星完成签到 ,获得积分10
13秒前
精明尔芙敏完成签到 ,获得积分10
16秒前
aaa完成签到,获得积分10
18秒前
开心的人杰完成签到,获得积分10
18秒前
神外王001完成签到 ,获得积分10
18秒前
兰亭序完成签到 ,获得积分10
19秒前
SSDlk完成签到,获得积分10
19秒前
22秒前
沉静的清涟完成签到,获得积分10
23秒前
啊啊啊啊啊啊啊完成签到,获得积分10
25秒前
26秒前
认真的半青完成签到 ,获得积分10
26秒前
Xu发布了新的文献求助10
27秒前
魔幻的惜灵完成签到 ,获得积分10
29秒前
完美幻桃完成签到,获得积分10
30秒前
解方程组完成签到,获得积分10
31秒前
任性星星完成签到 ,获得积分10
32秒前
power完成签到 ,获得积分10
32秒前
lx完成签到,获得积分10
32秒前
蔡琪发布了新的文献求助10
33秒前
怕孤单的以寒完成签到 ,获得积分10
33秒前
淡定又夏完成签到 ,获得积分10
34秒前
像风一样完成签到,获得积分10
37秒前
雷霆宝贝完成签到 ,获得积分10
38秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166556
求助须知:如何正确求助?哪些是违规求助? 9559576
关于积分的说明 21750809
捐赠科研通 7757392
什么是DOI,文献DOI怎么找? 3429167
关于科研通互助平台的介绍 2553530
邀请新用户注册赠送积分活动 2473923